Keyword: Imfinzi (durvalumab)
Will Mystic make it? That’s been the pressing question for AZ for months as the lung cancer trial proceeded. Answer: It didn’t, at least not yet.
The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—one its Bristol-Myers rival Opdivo met last year.
Investors are prepping for AstraZeneca's forthcoming Mystic data, which could shift the I-O landscape and AZ's fortunes, too.
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.
It’s good to be Merck these days. Less than a week after Keytruda nabbed an FDA go-ahead in bladder cancer, it scored a speedy review in stomach cancer.
The FDA has approved an immuno-oncology med as a new treatment for bladder cancer—for the third week in a row. Only this one has positive overall survival data under its belt.
So much has happened in the immuno-oncology field over the last two weeks that, frankly, we at FiercePharma aren’t sure we even recognize it anymore.
After its first FDA nod for Imfinzi, AstraZeneca is out with more positive data for the checkpoint inhibitor. But this time, it could boost the entire I-O field.